Vanda Pharmaceuticals - Worst Pharma Stocks of 2007
Company: Vanda Pharmaceuticals
Starting stock price: $24.83
Ending stock price: $6.88
Percent Change: -72.29%
Details: Vanda Pharmaceuticals has three in-development candidates, all focused on nervous system disorders. In September 2007, it filed a NDA for its antipsychotic med iloperidone. In a clinical trial the drug showed efficacy against schizophrenia symptoms but some developed an irregular heartbeat; the company plans to couple genetic testing with its drug to identify those likely to experience the heart problem. Its two other possibles are targeted at sleep and mood problems. One is in Phase III and the other recently wrapped up a Phase II study.
More News:
Vanda gains on late-stage sleep trial data. Report
More stories about Vanda Pharmaceuticals
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
